58 related articles for article (PubMed ID: 21677458)
1. Prognostic impact of phosphorylated mitogen-activated protein kinase expression in patients with metastatic gastric cancer.
Atmaca A; Pauligk C; Steinmetz K; Altmannsberger HM; Jäger E; Al-Batran SE
Oncology; 2011; 80(1-2):130-4. PubMed ID: 21677458
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer.
Gee JM; Robertson JF; Ellis IO; Nicholson RI
Int J Cancer; 2001 Jul; 95(4):247-54. PubMed ID: 11400118
[TBL] [Abstract][Full Text] [Related]
3. Association between phosphorylated AMP-activated protein kinase and MAPK3/1 expression and prognosis for patients with gastric cancer.
Kim JG; Lee SJ; Chae YS; Kang BW; Lee YJ; Oh SY; Kim MC; Kim KH; Kim SJ
Oncology; 2013; 85(2):78-85. PubMed ID: 23860205
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
Esteva FJ; Sahin AA; Smith TL; Yang Y; Pusztai L; Nahta R; Buchholz TA; Buzdar AU; Hortobagyi GN; Bacus SS
Cancer; 2004 Feb; 100(3):499-506. PubMed ID: 14745865
[TBL] [Abstract][Full Text] [Related]
5. Biological and prognostic relevance of mitogen-activated protein kinases in pancreatic adenocarcinoma.
Handra-Luca A; Lesty C; Hammel P; Sauvanet A; Rebours V; Martin A; Fagard R; Fléjou JF; Faivre S; Bédossa P; Ruszniewski P; Couvelard A
Pancreas; 2012 Apr; 41(3):416-21. PubMed ID: 22158075
[TBL] [Abstract][Full Text] [Related]
6. Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis.
Mizumoto Y; Kyo S; Mori N; Sakaguchi J; Ohno S; Maida Y; Hashimoto M; Takakura M; Inoue M
Cancer Sci; 2007 May; 98(5):652-8. PubMed ID: 17388789
[TBL] [Abstract][Full Text] [Related]
7. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma.
Pelloski CE; Lin E; Zhang L; Yung WK; Colman H; Liu JL; Woo SY; Heimberger AB; Suki D; Prados M; Chang S; Barker FG; Fuller GN; Aldape KD
Clin Cancer Res; 2006 Jul; 12(13):3935-41. PubMed ID: 16818690
[TBL] [Abstract][Full Text] [Related]
8. Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer.
Kim JW; Cho HJ; Kim M; Lee KH; Kim MA; Han SW; Oh DY; Lee HJ; Im SA; Kim TY; Yang HK; Kim WH; Bang YJ
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1435-43. PubMed ID: 23633032
[TBL] [Abstract][Full Text] [Related]
9. PTEN, Akt, MAPK, p53 and p95 expression to predict trastuzumab resistance in HER2 positive breast cancer.
Duman BB; Sahin B; Acikalin A; Ergin M; Zorludemir S
J BUON; 2013; 18(1):44-50. PubMed ID: 23613387
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
11. Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy.
Lee J; Park CK; Park JO; Lim T; Park YS; Lim HY; Lee I; Sohn TS; Noh JH; Heo JS; Kim S; Lim DH; Kim KM; Kang WK
Clin Cancer Res; 2008 Jan; 14(1):82-8. PubMed ID: 18172256
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of SKP2 and phospho-MAPK/ERK1/2 and decreased expression of p27 during tumor progression of cervical neoplasms.
Chen TP; Chen CM; Chang HW; Wang JS; Chang WC; Hsu SI; Cho CL
Gynecol Oncol; 2007 Mar; 104(3):516-23. PubMed ID: 17079005
[TBL] [Abstract][Full Text] [Related]
13. Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy.
Zhang YY; Gu KS; Wu HY; Yang F; Bu LJ; Zhao CC; Zhang YR
Genet Mol Res; 2015 Dec; 14(4):15921-9. PubMed ID: 26662383
[TBL] [Abstract][Full Text] [Related]
14. Perioperative chemotherapy for resectable gastroesophageal cancer: a single-center experience.
Molina R; Lamarca A; Martínez-Amores B; Gutiérrez A; Blázquez A; López A; Granell J; Álvarez-Mon M
Eur J Surg Oncol; 2013 Aug; 39(8):814-22. PubMed ID: 23755989
[TBL] [Abstract][Full Text] [Related]
15. [Expression of ERK1/2 MAPK signaling transduction pathway in esophageal cancers in Kazakh patients].
Zheng ST; Liu T; Middottuersun A; Huo Q; Liu Q; Huang CG; Feng JG; Lü GD; Wang X; Lin RY; Sheyhidin I; Lu XM
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):421-5. PubMed ID: 21875481
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
17. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
Ohrling K; Edler D; Hallström M; Ragnhammar P
Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
[TBL] [Abstract][Full Text] [Related]
18. Selective reduction of extracellular signal-regulated protein kinase (ERK) phosphorylation in squamous cell carcinoma of the larynx.
Garavello W; Nicolini G; Aguzzi A; Maggioni D; Leone BE; Viganò P; Gaini RM; Tredici G
Oncol Rep; 2006 Sep; 16(3):479-84. PubMed ID: 16865246
[TBL] [Abstract][Full Text] [Related]
19. HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: a prospective cohort observation.
Qiu MZ; Li Q; Wang ZQ; Liu TS; Liu Q; Wei XL; Jin Y; Wang DS; Ren C; Bai L; Zhang DS; Wang FH; Li YH; Xu RH
Int J Cancer; 2014 May; 134(10):2468-77. PubMed ID: 24155030
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.
Van Cutsem E; de Haas S; Kang YK; Ohtsu A; Tebbutt NC; Ming Xu J; Peng Yong W; Langer B; Delmar P; Scherer SJ; Shah MA
J Clin Oncol; 2012 Jun; 30(17):2119-27. PubMed ID: 22565005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
